These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8205 related articles for article (PubMed ID: 26784400)

  • 1. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/MR imaging of lymphoma nodal target lesions: Comparison of PET standardized uptake value (SUV) with MR apparent diffusion coefficient (ADC).
    Bernstine H; Domachevsky L; Nidam M; Goldberg N; Abadi-Korek I; Shpilberg O; Groshar D
    Medicine (Baltimore); 2018 Apr; 97(16):e0490. PubMed ID: 29668631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
    Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
    J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging.
    Giraudo C; Karanikas G; Weber M; Raderer M; Jaeger U; Simonitsch-Klupp I; Mayerhoefer ME
    J Magn Reson Imaging; 2018 May; 47(5):1217-1226. PubMed ID: 29086453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
    Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
    Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients.
    Atkinson W; Catana C; Abramson JS; Arabasz G; McDermott S; Catalano O; Muse V; Blake MA; Barnes J; Shelly M; Hochberg E; Rosen BR; Guimaraes AR
    Abdom Radiol (NY); 2016 Jul; 41(7):1338-48. PubMed ID: 27315095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/MRI for the evaluation of patients with lymphoma: initial observations.
    Heacock L; Weissbrot J; Raad R; Campbell N; Friedman KP; Ponzo F; Chandarana H
    AJR Am J Roentgenol; 2015 Apr; 204(4):842-8. PubMed ID: 25794075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body MRI versus an [
    Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; de Keizer B; Nievelstein RAJ
    Eur Radiol; 2021 Dec; 31(12):8925-8936. PubMed ID: 34021390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of diffusion-weighted MRI and [
    Morakote W; Baratto L; Ramasamy SK; Adams LC; Liang T; Sarrami AH; Daldrup-Link HE
    Eur Radiol; 2024 Jan; 34(1):643-653. PubMed ID: 37542653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
    Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
    AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
    Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
    Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
    Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 411.